Partner.Co publishes four items under the heading Clinical Studies. Three are written by its own scientists and one is a conference talk. Here is what each one tested, and what it can and cannot tell you.
Supplement brands like the word published. It sounds like peer review, independence and rigour, and it usually is doing none of that work. So rather than repeat the headline figures, here is a plain reading of the four items Partner.Co lists as clinical studies, what each actually is, and where you can read it.
One thing up front, because it shapes everything below: three of the four are written by Partner.Co's own research and development team, about Partner.Co's own products. That is common in this industry and it is not by itself disqualifying. Manufacturers fund most nutrition research because nobody else will. It does mean the work carries the weight of an interested party rather than a neutral one, and it is a fact you should have before you read a percentage.
The Optimals survey, and why 82 percent is not what it looks like
The most quoted figure in the set is that 82.41 percent of participants reported improvement in energy or stamina after taking Nutrifii Optimal-V and Optimal-M. It comes from a paper in the ARC Journal of Nutrition and Growth, authored by Partner.Co's Brett West, Melissa Reid and Fernando Swartz.
Here is what that study was. One hundred and four people took the products for eight weeks and were then asked whether they felt better. There was no placebo group, nobody was blinded, and nothing was measured. Every one of those percentages is a record of what people said about themselves, knowing what they had taken and why they were being asked.
That design cannot separate a product's effect from the ordinary human tendency to feel better about something you chose, paid for and committed to for two months. Placebo response in self-reported energy and wellbeing runs high in controlled trials precisely because those outcomes are so responsive to expectation. This is why a control group is not a formality.
What the survey does establish is that people who took these products for eight weeks mostly reported a good experience, and that is genuinely worth something when you are deciding whether to try something. It is customer satisfaction data. It is not evidence of an effect.
The immune function paper is a review, not an experiment
The Influence of Noni Fruit Juice on Immune System Function appeared in the Journal of Biosciences and Medicines in December 2023, again from Partner.Co's research team. It is frequently cited as though the company ran a study. It did not. The paper gathers and discusses existing human and animal research on how noni juice might affect immune signalling, including work on interleukin-2 and natural killer cell activity.
A review is a legitimate and useful form of scientific writing. It is also the form in which an author has the most latitude to choose which studies to include, which makes independence matter more rather than less. Read it as a well-informed summary from an interested party, and follow its citations to the underlying papers if a specific claim matters to you. Those underlying papers are the real evidence, and several of them are genuinely independent.
The antioxidant paper, and a product we do not sell
A 2024 paper in the World Journal of Advanced Pharmaceutical and Medical Research reports that Tahitian Noni MAX raised antioxidant activity in blood samples far above a blood orange juice comparator, by figures in the region of 28 and 49 times. The authors are Partner.Co's Brett West and Shixin Deng.
Two things to know. The number of human participants is not stated in the company's own summary of the work, and a ratio without a sample size behind it is not interpretable. And more simply: Tahitian Noni MAX is not a product this shop carries. Our noni products are the juice and the pouches. Whatever this paper shows, it does not transfer to a different formulation, and you should be suspicious of any retailer who implies otherwise.
Where the journals sit
All three papers appear in small open-access journals rather than established titles in nutrition science. Open access is not a mark against a journal by itself, but at the smaller end of the market the fee is paid by the author and the review can be thin or effectively absent. Publication in these venues tells you that the work was written up and paid for. It does not tell you that independent specialists scrutinised it and were satisfied.
The fourth item, a conference presentation on counterfeit noni powders sold on marketplaces, is covered in its own article. It is the strongest of the four, and it is also not peer reviewed.
Reading it for yourself
We sell these products, which is worth knowing when you read anything here about the research behind them.
There is real independent research behind parts of this catalogue, including work on fucoidan and on noni that Partner.Co did not pay for. The four studies above are not that. The papers are named and the journals are searchable, so any of this can be checked.